Publication | Closed Access

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

Tumor ImmunologyCancer ImmunosurveillanceT CellsT-regulatory CellImmunologyHuman T-cell MalignanciesImmune Cell TherapyImmunotherapyMedicineRadiation OncologySynthetic ImmunologyPreclinical Targeting